Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Dose-Escalation Study of STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Phase of Trial: Phase II
Latest Information Update: 23 May 2017
At a glance
- Drugs STX 100 (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions
- Sponsors Biogen
- 18 May 2017 Status changed from active, no longer recruiting to completed.
- 26 Apr 2017 Status changed from recruiting to active, no longer recruiting.
- 11 Apr 2017 Planned number of patients changed from 40 to 41.